- Home
- WERN vs AAPG Comparison
WERN vs AAPG Comparison
Compare WERN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | AAPG |
|---|---|---|
| Founded | 1956 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | WERN | AAPG |
|---|---|---|
| Price | $40.78 | $20.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $33.79 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.2M | 5.1K |
| Earning Date | 04-28-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,974,396,000.00 | N/A |
| Revenue This Year | $22.24 | $290.34 |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.06 | $18.56 |
| 52 Week High | $40.11 | $48.45 |
Technical Indicators
Market Signals| Indicator | WERN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 73.20 | 40.62 |
| Support Level | $30.30 | $20.11 |
| Resistance Level | N/A | $25.23 |
| Average True Range (ATR) | 1.48 | 0.79 |
| MACD | 0.34 | 0.05 |
| Stochastic Oscillator | 95.15 | 38.98 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.